INTRODUCTION {#S1}
============

Generalized vitiligo (GV) is a complex disorder in which acquired, progressive, multifocal loss of pigmentation of skin and hair results from loss of melanocytes from the affected areas ([@R58]; [@R10]). While the striking phenotype of GV has been recognized for thousands of years ([@R43]), its underlying pathobiology has remained largely unknown, despite the suggestion of numerous theories ([@R12]; [@R45]). Some of the earliest attempts to understand the biology of GV considered its possible genetic basis, in the hope that understanding the genetics would lead to insights into basic pathogenetic mechanisms of disease ([@R56]; [@R59]; Lerner, 1959). Over the next four decades, various types of genetic studies aimed to discover genes involved in mediating GV susceptibility, with limited success. However, recently genomewide genetic association studies have succeeded in identifying a veritable cornucopia of GV susceptibility genes, encoding components of biological networks that largely regulate elements of the immune system and their targeting and destruction of melanocytes.

EPIDEMIOLOGICAL STUDIES {#S2}
=======================

Probably the earliest evidence relating to the genetic basis of vitiligo was the 1855 description by Addison, of a patient with idiopathic adrenal insufficiency (now known as Addison's disease), GV, and pernicious anemia ([@R1]). Over the next century numerous case reports described co-occurrence of GV and various other autoimmune diseases, and in 1908 Claude suggested the likelihood of a causal connection among autoimmune diseases that tended to occur concomitantly ([@R14]).

In 1926 Schmidt codified the concomitant occurrence of Addison's disease and autoimmune thyroid disease, in what came to be called "Schmidt syndrome" ([@R50]), and in1980 Neufeld and Blizzard re-classified the so-called "autoimmune polyglandular syndromes" (APS), denoting a rare autosomal recessive form (sometimes including GV) as APS-1, denoting Schmidt syndrome (sometimes including GV) as APS-2, denoting concomitant occurrence of autoimmune thyroid disease with at least one other autoimmune disease (again, often including GV) as APS-3, and denoting all other combinations of autoimmune diseases as APS-4 ([@R42]). While there have been a number of subsequent attempts to refine the APS classification, except for APS-1 (now renamed APECED; autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy, resulting from mutations in the *AIRE* gene), this system is no longer widely used. Instead, it has become clear that "multiple autoimmune disease" is more complex, and that GV is part of a more general autoimmune disease diathesis. Indeed, the frequencies of many other autoimmune diseases, particularly including autoimmune thyroid disease (Hashimoto's thyroiditis and Graves' disease), adult-onset type 1 diabetes mellitus, rheumatoid arthritis, psoriasis, pernicious anemia, Addison's disease, and systemic lupus erythematosus (SLE), are elevated among GV patients ([@R3]; [@R33]; [@R57]). Furthermore, the frequencies of these same autoimmune diseases are elevated among the first-degree relatives of GV patients, even those who do not have GV ([@R3]; [@R33]). This has led to the belief that general susceptibility to autoimmunity is a complex trait involving various shared susceptibility genes, while other genes and exposure to unknown environmental triggers determine the occurrence of GV and other specific autoimmune diseases in individual patients ([@R53]).

In addition, genetic epidemiological studies have addressed the likely mode of inheritance of GV. While there had been a number of previous case reports describing the occurrence of GV in occasional relatives, perhaps the first to address the inheritance of GV specifically were [@R56] and [@R59], who described multigenerational families with multiple cases of GV ("multiplex families") and other autoimmune diseases, concluding that autosomal dominant inheritance seemed likely. Based on a survey of 128 vitiligo patients, Lerner (1959) noted that 38% reported affected relatives, and concluded the "disease is often transmitted as a dominant trait." However, while many subsequent patient surveys around the world confirmed frequent clustering of vitiligo cases within families (*e.g*. [@R39]; [@R23]; [@R44]; [@R15]; [@R6]; [@R38]; [@R32]; [@R3]; [@R57]), a single-locus Mendelian pattern of inheritance was not supported, and most favored a polygenic, multifactorial model involving multiple genes and also environmental risk factors, what is now termed a "complex trait". An major environmental component in GV is also indicated by its limited concordance in monozygotic twins; among 22 such twin-pairs, [@R3] reported a concordance of only 23%, underscoring the importance of environmental triggers in disease pathogenesis.

CANDIDATE GENE ASSOCIATION STUDIES {#S3}
==================================

The earliest analyses testing the involvement of specific genes in the pathogenesis of GV were candidate gene association studies, of HLA ([@R49]), ABO ([@R30]), and other blood groups ([@R63]), and were generally negative. A large number of 'positive' candidate gene associations with GV have been reported subsequently (reviewed in [@R9]). However, candidate gene association studies of complex diseases have generally proven to be highly subject to false-positive artifacts, principally due to occult ethnic differences between cases and controls (population stratification) and inadequate correction for multiple-testing ([@R22]; [@R20]), and thus have fallen into general disfavor. Except for *HLA* and *PTPN22*, most candidate gene associations reported for GV have not been confirmed by subsequent studies (reviewed in [@R9]).

GENOMEWIDE LINKAGE STUDIES {#S4}
==========================

Genomewide linkage and association studies are not biased by *a priori* biological hypotheses and are less subject to methodological pitfalls than are candidate gene approaches. Genetic linkage studies are best suited to detecting relatively rare disease susceptibility alleles with large effects, as in multiplex families. While genetic linkage studies are typically carried out genomewide, in fact the first linkage analysis reported for GV was a negative study, testing linkage of a candidate gene, *MITF* ([@R62]). The first direct genomewide linkage study of GV, in a unique large Caucasian kindred with apparent autosomal dominant inheritance with incomplete penetrance, detected linkage in chromosome 1p31.3--p32.2 ("*AIS1*"; Alkhateeb et al., 2001). Subsequent DNA sequence analysis of genes in the chromosome 1p linkage interval identified a transcriptional regulatory variant of *FOXD3*, which encodes Forkhead box D3), a key regulator of melanoblast lineage differentiation and development ([@R4]).

Genomewide linkage studies of many other Caucasian multiplex GV families identified additional linkage signals on chromosomes 7, 8, 9, 11, 13, 17, 19, and 22 ([@R18]; [@R52]). The strongest of these signals, on chromosome 17p13, coincided with *SLEV1*, a linkage signal for SLE detected in families that also included at least one relative with GV ([@R41]) or other autoimmune diseases ([@R29]). Targeted family-based genetic association analysis of SNPs spanning the chromosome 17p linkage interval identified the corresponding gene as *NALP1* (now renamed *NLRP1*), encoding NACHT, LRR, and PYD domains-containing protein 1 ([@R25]), a key regulator of the innate immune system that apparently acts as a sentinel for bacterial infection in the skin ([@R34]). Several studies have subsequently confirmed association of *NLRP1* with GV, ([@R24]; [@R5]), and also with type 1 diabetes (Magitta et al., 2008), Addison's disease (Magitta et al., 2008; [@R64]), celiac disease ([@R46]), systemic sclerosis ([@R17]), and perhaps inflammatory bowel disease ([@R16]).

Parallel genetic linkage studies of GV in Han Chinese detected linkage signals on chromosomes 1, 4, 6, 14, and 22 ([@R13]; [@R35]). These linkage signals generally did not correspond to those detected in Caucasian families, suggesting that different genes might underlie GV susceptibility in these different populations. By candidate gene association analysis of several genes located within the chromosome 22q12.1--12.3 linkage peak, [@R48] subsequently identified *XBP1*, encoding transcription factor X-box binding protein 1, which activates MHC class II gene expression, regulates plasma cell differentiation, and mediates inflammatory response to endoplasmic reticulum stress. Additional support for involvement of *XBP1* in the pathogenesis of GV came from a subsequent genomewide association study of Caucasians ([@R9]), and *XBP1* has been independently associated with genetic risk of Crohn's disease ([@R31]).

GENOMEWIDE ASSOCIATION STUDIES {#S5}
==============================

Genomewide association studies (GWAS) are best suited to detecting relatively common disease susceptibility alleles with modest effects, as may be most relevant to typical singleton cases of a complex disease such as GV. Of particular importance, GWAS can adequately correct for both population stratification and multiple-testing ([@R22]; [@R20]), and so are currently considered the "gold standard" for identifying complex trait susceptibility genes.

The first GV GWAS ([@R8]) involved a "special population", an isolated village with a very high prevalence of GV located in the mountains of northwestern Romania ([@R7]). This analysis detected GV association with SNPs in distal chromosome 6q27, in the vicinity of *IDDM8*, a linkage and association signal for type I diabetes mellitus and rheumatoid arthritis.

A subsequent, much larger GWAS in Caucasians detected at least 13 different GV susceptibility loci ([@R26],[@R27]; [Table 1](#T1){ref-type="table"}), and confirmed three others that had been reported in previous candidate gene studies ([@R9]). A parallel GV GWAS in Chinese ([@R47]) detected two association signals, one or both of which were among those detected in Caucasians ([Table 1](#T1){ref-type="table"}). In both the Caucasian and Chinese studies, strong GV association signals were detected in the major histocompatibility complex (MHC) on chromosome 6p21.3. In Caucasians, independent associations were detected in both the MHC class I and class II gene regions. In the class I region, the major association signal was in the vicinity of *HLA-A*, in strong linkage disequilibrium with *HLA-A\*02*. In the class II region, the major association signal was located between *HLA-DRB1* and *HLA-DQA1*, in moderate linkage disequilibrium with *HLA-DRB1*\*04 ([@R26]). These results are thus consistent with previous reports of association of GV with both *HLA-A*\*02 ([@R36]) and *HLA-DRB1*\*04 ([@R19]) alleles. However, in Chinese, the major MHC association signal was in the class III gene region, with some evidence for additional association in the class II gene region ([@R47]).

Perhaps more important, these two large-scale GV GWASs also detected association with a number of non-MHC loci, almost all of which encode immunoregulatory proteins. The Caucasian GWAS ([@R26],[@R27]) detected associations with at least ten non-MHC loci: *TYR* (tyrosinase), *PTPN22* (lymphoid-specific protein tyrosine phosphatase nonreceptor type 22), *RERE* (arginine-glutamic acid dipeptide \[RE\] repeats protein; atrophin-like protein 1), *FOXP1* (forkhead box P1), *LPP* (LIM domain-containing preferred translocation partner in lipoma), *IL2RA* (interleukin-2-receptor alpha chain), *GZMB* (granzyme B), *UBASH3A* (ubiquitin-associated and SH3 domain-containing A), *C1QTNF6* (C1q and tumor necrosis factor-related protein 6), and *CCR6* (C-C chemokine receptor type 6). This last gene is located very close to the 6q27 association signal detected in the Romanian village ([@R8]), and was the only non-MHC locus detected in the Chinese GWAS ([@R47]). The Caucasian GWAS also provided evidence of association of GV with additional loci previously suggested as candidate genes for GV: *XBP1* (see above), *FOXP3* (forkhead box P3), *TSLP* (thymic stromal lymphoprotein), and *CTLA4* (cytotoxic T-lymphocyte antigen 4), though as in previous studies association of GV with *CTLA4* appeared to reflect primary association with other concomitant autoimmune diseases in the GV cases, rather than with GV itself ([@R9]).

Among the most illuminating associations with GV are those of MHC class I and *TYR*, which together highlight one of the pathways by which the immune system "sees" and thus targets melanocytes. The MHC class I association in Caucasians with GV is with SNP rs12206499, which tags *HLA-A\*02* (predominantly *HLA-A\*02:01*), while the *TYR* association with GV is with the major (R; Arg) allele of the R402Q polymorphism (SNP rs1126809) that is relatively common among Caucasians (minor allele frequency 0.22 to 0.40) but is rare in other populations ([@R61]). In contrast, the minor (Q; Gln) allele of the *TYR* R402Q polymorphism is associated with susceptibility to malignant melanoma ([@R21]; [@R11]), while *HLA-A\*02* is associated with relatively favorable response to melanoma immunotherapy ([@R40]). Tyrosinase is a major GV autoantigen presented to the immune system on the surface of melanocytes and melanoma cells by HLA class I molecules, principally HLA-A\*02. One of the important epitopes presented by HLA-A\*02 is a modified tyrosinase nonapeptide, YMDGTMSQV ([@R51]). However, the variant 402Q form of tyrosinase is hypoglycosylated ([@R60]), which in turn would prevent the modification that is essential for its antigenic presentation by HLA-A\*02. As the result, tyrosinase-402R likely makes a quantitatively greater contribution than tyrosinase-402Q to presentation of antigenic tyrosinase by HLA-A\*02. Together, these findings indicate an apparent inverse relationship between genetic susceptibility to GV and genetic susceptibility to malignant melanoma as mediated by *TYR* and *HLA-A\*02* ([@R26]), suggesting that GV may represent a dysregulated mechanism of immune surveillance against malignant melanoma, with *TYR* R402Q modulating immune recognition of melanocytes by modulating availability of tyrosinase peptide for presentation by HLA-A\*02 ([@R54]).

In addition to primary searches for genes that influence disease susceptibility *per se*, genomewide approaches can also be used to identify genes that influence the natural history of disease. Such an approach has recently been taken to identify a locus that contributes to GV age of onset ([@R28]). These authors' reanalyzed their previous GV GWAS dataset, considering only the affected individuals, in whom GV age of onset was assessed as a quantitative trait. This analysis identified a major GV age of onset locus in the MHC class II region, apparently reflecting the same locus that was associated with GV susceptibility ([@R26]), while none of the other loci that had been associated with GV susceptibility *per se* were associated with age of onset. These results suggest that some loci likely mediate GV susceptibility *per se*, whereas other loci, particularly variation in the MHC class II region, might mediate response to environmental triggers encountered over the course of life, thereby influencing age of disease onset.

PERSPECTIVE {#S6}
===========

For GV as for many other complex diseases, application of genomewide approaches, particularly GWAS, has resulted in rapid progress in identifying true disease susceptibility genes, while most genes suggested as *a priori* biologically-based candidates have remained unconfirmed. Accordingly, for GV as for many other diseases, we have entered a new era of understanding the true underlying pathobiology, which in the case of GV appears to be predominantly autoimmune. Furthermore, many of the genes that are genetically associated with GV are also genetically associated with some of the other autoimmune diseases with which GV is epidemiologically associated, confirming the longstanding hypothesis that these epidemiological associations reflect underlying shared causal elements ([@R14]).

The studies carried out so far have identified a plethora of new biological pathways that constitute potential targets for therapeutic intervention and perhaps even disease prevention. However, these findings only scratch the surface, accounting for a relatively small portion of total disease risk. Larger genomewide studies can be expected to identify even more GV susceptibility genes and thus shed even more light on the nature of the disease, and perhaps even provide clues to environmental triggers. Moreover, for only a few of the GV susceptibility genes found thus far have the corresponding underlying causal variants been identified; this will require extensive DNA sequencing of large numbers of GV patients, careful bioinformatics analysis, and targeted functional studies to assess the effects of specific variants, both individually and in combination. Nevertheless, the way forward is now clear, with many doors opening to new understanding and new opportunities for treating patients with GV.
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Loci with confirmed involvement in GV susceptibility on the basis of genomewide studies[1](#TFN1){ref-type="table-fn"}

  Chromosome   Gene                                          Protein                                                              Function                                                                                                                            Causal Variant   Other Autoimmune Disease Associations
  ------------ --------------------------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- ---------------- -----------------------------------------------------------------------------------------------------------------------
  1p36.23      *RERE*                                        Atrophin-like protein 1                                              Regulates apoptosis                                                                                                                                  
  1p13.2       *PTPN22*                                      Lymphoid-specific protein tyrosine phosphatase nonreceptor type 22   Regulates T cell receptor signaling                                                                                                 R620[W]{.ul}     Type 1 diabetes, SLE, Graves' disease, rheumatoid arthritis, Addison's disease, psoriasis, inflammatory bowel disease
  2q33.2       *CTLA4*[2](#TFN2){ref-type="table-fn"}        Cytotoxic T-lymphocyte antigen 4                                     Inhibits T cells                                                                                                                                     Type 1 diabetes, Graves' disease, Hashimoto's thyroiditis, inflammatory bowel disease, SLE
  3p13         *FOXP1*                                       Forkhead box P1                                                      Regulates lymphoid cell development                                                                                                                  
  3q28         *LPP*                                         LIM domain-containing preferred translocation partner in lipoma      Unknown                                                                                                                                              Celiac disease, rheumatoid arthritis
  5q22.1       *TSLP*                                        Thymic stromal lymphoprotein                                         Regulates T cell and dendritic cell maturation                                                                                                       
  6p21.3       MHC class I (*HLA-A*)                         Human leukocyte antigen α chain                                      Presents peptide antigens                                                                                                           [\*02:01]{.ul}   Many
               MHC class II[3](#TFN3){ref-type="table-fn"}   Unknown                                                                                                                                                                                                                   Many
               MHC class III                                 Unknown                                                                                                                                                                                                                   Many
  6q27         *CCR6*                                        C-C chemokine receptor type 6                                        Regulates B cell differentiation, function of dendritic and Th17 cells                                                                               Inflammatory bowel disease, rheumatoid arthritis, Graves' disease
  10p15.1      *IL2RA*                                       Interleukin-2 receptor α chain                                       Regulates lymphocyte response to bacteria via IL2                                                                                                    Type 1 diabetes, Graves' disease, multiple sclerosis, rheumatoid arthritis, SLE
  11q14.3      *TYR*                                         Tyrosinase                                                           Key enzyme of melanin biosynthesis                                                                                                  [R]{.ul}402Q     
  14q12        *GZMB*                                        Granzyme B                                                           Mediates target cell apoptosis by cytotoxic T cells and natural killer cells, activation-induced cell death of effector Th2 cells                    
  17p13.2      *NLRP1*                                       NACHT, LRR, and PYD domains-containing protein 1                                                                                                                                                                          Type 1 diabetes, Addison's disease, celiac disease, systemic sclerosis
  21q22.3      *UBASH3A*                                     Ubiquitin-associated and SH3 domain containing A                     Regulates T cell receptor signaling                                                                                                                  Type 1 diabetes
  22q12.1      *XBP1*                                        X-box binding protein 1                                              Regulates expression of MHC class II genes, IL6, B cell and plasma cell differentiation                                                              Crohn's disease
  22q13.1      *C1QTNF6*                                     C1q and tumor necrosis factor-related protein 6                      Unknown                                                                                                                                              Type 1 diabetes, rheumatoid arthritis
  Xp11.23      *FOXP3*                                       Forkhead box P3                                                      Regulates regulatory T cells                                                                                                                         Defective gene in Immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX)

Adapted from [@R55].

Numerous studies have indicated that *CTLA4* is only associated with GV in patients who also have other autoimmune diseases, suggesting that apparent association of *CLTA4* with GV is secondary to epidemiological association with these other diseases.

The MHC class II region is associated with both GV susceptibility and age of onset.
